| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 7860444 | Journal of Controlled Release | 2018 | 51 Pages |
Abstract
203P-glycoprotein transporter limits the success of doxorubicin-based chemotherapy. Here we produced two different formulations of folic acid-decorated liposomes, carrying a synthetic doxorubicin conjugated with nitric oxide-releasing group, able to inhibit P-glycoprotein efflux. These formulations induced huge folic acid receptor-dependent uptake, high delivery and cytotoxicity of doxorubicin in P-glycoprotein-positive breast cancer cells, and significantly higher anti-tumor effects against folic acid-positive/Pgp-positive breast tumors refractory to free doxorubicin and Caelyx®.
Related Topics
Physical Sciences and Engineering
Materials Science
Biomaterials
Authors
Elena Gazzano, Barbara Rolando, Konstantin Chegaev, Iris C. Salaroglio, Joanna Kopecka, Isabella Pedrini, Simona Saponara, Matteo Sorge, Ilaria Buondonno, Barbara Stella, Alessandro Marengo, Massimo Valoti, Mara Brancaccio, Roberta Fruttero,